Oncology
Cancer drug developers across modalities and stages — a broad disease-area basket, not a single play.
Scope: Disease-area basket spanning many modalities and stages; leadership here is a broad biotech-risk reading, not a single investable play.
Leadership as of 2026-10-27: Lagging. Relative to SPY: 5 sessions −1.9pp, 21 sessions −8.2pp, 63 sessions −7.4pp. Participation 32%; 29 of 34 members eligible.
- 21-session excess -8.2pp
- 63-session excess -12.4pp (robust)
Economic family: Biotechnology
Member companies
- Verastem, Inc. (VSTM)
- Replimune Group, Inc. (REPL)
- SELLAS Life Sciences Group, Inc (SLS)
- Exelixis, Inc. (EXEL)
- Rigel Pharmaceuticals, Inc. (RIGL)
- ImmunityBio, Inc. (IBRX)
- Relay Therapeutics, Inc. (RLAY)
- Erasca, Inc. (ERAS)
- Revolution Medicines, Inc. (RVMD)
- Janux Therapeutics, Inc. (JANX)
- Inhibrx Biosciences, Inc. (INBX)
- Kura Oncology, Inc. (KURA)
- Tango Therapeutics, Inc. (TNGX)
- Candel Therapeutics, Inc. (CADL)
- Summit Therapeutics Inc. (SMMT)
- CG Oncology, Inc. (CGON)
- IDEAYA Biosciences, Inc. (IDYA)
- Cogent Biosciences, Inc. (COGT)
- Faeth Therapeutics, Inc. (FTH)
- Bicara Therapeutics Inc. (BCAX)
- Tyra Biosciences, Inc. (TYRA)
- Immunome, Inc. (IMNM)
- Oric Pharmaceuticals, Inc. (ORIC)
- Celcuity Inc. (CELC)
- Arcus Biosciences, Inc. (RCUS)
- Syndax Pharmaceuticals, Inc. (SNDX)
- Olema Pharmaceuticals, Inc. (OLMA)
- ArriVent BioPharma, Inc. (AVBP)
- Aktis Oncology, Inc. (AKTS)
- Aura Biosciences, Inc. (AURA)
- BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Crescent Biopharma, Inc. (CBIO)
- CytomX Therapeutics, Inc. (CTMX)
- Geron Corporation (GERN)
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%